Saltsjobaden

Respiratory syncytial virus RSV commonly causes respiratory infections leading to hospitalizations, especially in infants and older adults. Arexvy is an approved vaccine aimed at preventing RSV infections, but there is limited data on its immune response in people aged 80 and older. This study aims to compare immune responses to Arexvy between adults aged 80 and above and those aged 60 to 65 to better understand vaccination effects in these age groups. Participants will receive an initial dose of the Arexvy vaccine followed by a booster dose one year later. The study includes two groups adults aged 60 to 65 living in the community and adults aged 80 and above, including those in long-term care facilities. Vaccinations and follow-ups will be conducted at designated clinical centers and care facilities, with an open-label design and no placebo group. Throughout the study, participants will be monitored for immune responses primarily around day 31 after vaccination, with secondary assessments extending up to 18 months. The study will collect data on antibody responses, vaccine safety, and reactogenicity. Participants will have regular visits for evaluations, and the research will provide insights into the vaccines effects in the oldest and frail populations over the study period.